澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MESOBLAST LTD

2.120

-0.030-1.40%

成交量：47.78萬

成交額：101.77萬

市值：27.49億

市盈率：-34.13

高：2.190

開：2.170

低：2.105

收：2.150

52周最高：3.310

52周最低：1.880

股本：12.97億

流通股本：7.86億

量比：0.64

換手率：0.06%

股息：- -

股息率：- -

每股收益(TTM):-0.062

每股收益(LYR):-0.062

淨資產收益率：-9.86%

總資產收益率：-4.11%

市淨率：3.46

市盈率(LYR):-34.13

資料載入中...

總覽公司新聞公告

Mesoblast Limited：預計短期內將持續面臨重大虧損

Mesoblast完成慢性腰痛關鍵性3期試驗患者治療，達成重大里程碑

Mesoblast報告Ryoncil®季度淨營收3600萬美元，產品上市首年淨營收達1.15億美元

Mesoblast首席執行官增持股份以強化股權

異動解讀 | Mesoblast公布Ryoncil收入強勁，股價盤中大漲5%

Mesoblast公布Ryoncil第四季度淨收入達3600萬美元

Mesoblast就Rexlemestrocel-l用於晚期心力衰竭伴左心室輔助裝置適應症向FDA提交模塊化BLA審查申請

Mesoblast公布Ryoncil®季度淨收入達3030萬美元運營現金流支出改善至410萬美元

異動解讀 | Mesoblast收購CAR平台技術，盤中大漲5.22%

Mesoblast收購嵌合抗原受體平台技術，推動精準增強型細胞產品發展

Mesoblast獲FDA批准可直接開展Ryoncil®治療杜氏肌營養不良症的註冊試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/MSB.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.12,"timestamp":1789351333802,"preClose":2.15,"halted":0,"volume":477808,"delay":0,"changeRate":-0.013953488372092933,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06212023062835172,"marketStatus":"交易中","change":-0.03,"latestTime":"09-14 12:02:20 AEST","open":2.17,"high":2.19,"low":2.105,"amount":1017696,"amplitude":0.039535,"askPrice":2.13,"askSize":57296,"bidPrice":2.12,"bidSize":67021,"shortable":3,"etf":0,"ttmEps":-0.06212023062835172,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789365600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.15,"openAndCloseTimeList":[[1789344000000,1789365600000]],"volumeRatio":0.635742,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.15,"auctionPrice":2.17,"auctionVolume":8324,"auctionTime":1789343949299,"referenceTime":1789122603091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789343949299}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.06212,"volumeRatio":0.635742,"shares":1296862776,"dividePrice":0,"high":2.19,"amplitude":0.039535,"preClose":2.15,"low":2.105,"week52Low":1.88,"pbRate":"3.46","psRate":"16.34","week52High":3.31,"institutionHeld":0,"latestPrice":2.12,"committee":0.078227,"eps":-0.06212023062835172,"divideRate":0,"volume":477808,"delay":0,"ttmEps":-0.06212023062835172,"open":2.17,"prevYearClose":2.72,"prevWeekClose":2.15,"prevMonthClose":2.36,"prevQuarterClose":1.955,"fiveDayClose":2.23,"twentyDayClose":2.45,"sixtyDayClose":2.16,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1198020721","title":"Mesoblast Limited：預計短期內將持續面臨重大虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=1198020721","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198020721?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 06:27","pubTimestamp":1787783223,"startTime":"0","endTime":"0","summary":"Mesoblast Limited近日发出预警，表明公司可能在未来可预见的一段时期内，继续承受显著的财务亏损。Mesoblast在研发上的持续投入，虽然从长远来看可能带来丰厚回报，但短期内却不可避免地加重了其财务负担。在当前生物科技板块波动加剧的背景下，Mesoblast的这一声明或将引发市场对其未来融资策略和现金流状况的更多关注。Mesoblast能否在亏损泥潭中找到突破口，市场正拭目以待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7508","BK7501","BK7067","BK4139","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176396021","title":"Mesoblast完成慢性腰痛關鍵性3期試驗患者治療，達成重大里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1176396021","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176396021?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 08:36","pubTimestamp":1786926968,"startTime":"0","endTime":"0","summary":"Mesoblast（MESOBLAST LTD）在治疗慢性腰痛的关键性3期临床试验中，已顺利完成全部患者的治疗工作。这一成就标志着该公司在推进这一潜在疗法上迈出了决定性的一步。临床试验的完成，不仅为后续的数据分析铺平了道路，也极大地提振了市场对这款创新疗法的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134208248","title":"Mesoblast報告Ryoncil®季度淨營收3600萬美元，產品上市首年淨營收達1.15億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134208248","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134208248?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 08:59","pubTimestamp":1785373168,"startTime":"0","endTime":"0","summary":"Mesoblast（股票代码：MSB.AU）公布了其核心产品Ryoncil®的财务表现。数据显示，该公司在最近一个季度录得净营收3600万美元（约合3600万美元）。不仅如此，从产品正式上市至今的第一个完整财年内，Ryoncil®累计贡献的净营收总额已达到1.15亿美元。这一成绩标志着该产品在商业化初期便展现出强劲的市场接纳度与增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157804936","title":"Mesoblast首席執行官增持股份以強化股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1157804936","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157804936?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 09:53","pubTimestamp":1784598831,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd宣布，其首席执行官已通过投资进一步增持公司股份。具体而言，该首席执行官行使了190万份股票期权，行权价为每股1.45澳元，总价值达273万澳元。此次交易后，其持股总数增加至8080万股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","MSB.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110478122","title":"異動解讀 | Mesoblast公布Ryoncil收入強勁，股價盤中大漲5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110478122","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110478122?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 11:14","pubTimestamp":1783653296,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd（MSB.AU）今日盘中大涨5.00%，引起了市场的广泛关注。消息面上，Mesoblast Ltd报告称，其产品Ryoncil在第四季度实现净收入3600万美元，全年累计净收入达到1.15亿美元，这一积极的财务表现增强了投资者对公司业务前景的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187543113","title":"Mesoblast公布Ryoncil第四季度淨收入達3600萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187543113","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187543113?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 09:28","pubTimestamp":1783646928,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd 报告称，其产品Ryoncil在第四季度实现净收入3600万美元，全年累计净收入达到1.15亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103471148","title":"Mesoblast就Rexlemestrocel-l用於晚期心力衰竭伴左心室輔助裝置適應症向FDA提交模塊化BLA審查申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1103471148","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103471148?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 15:48","pubTimestamp":1783324088,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) 已向美国食品药品监督管理局（FDA）提交申请，请求对其生物制品许可申请（BLA）进行模块化审查。该BLA旨在寻求批准其候选药物Rexlemestrocel-l，用于治疗晚期心力衰竭伴左心室辅助装置（LVAD）的患者。\n值得注意的是，Rexlemestrocel-l此前已获得FDA授予的孤儿药资格认定和再生医学先进疗法（RMAT）认定。这些认定旨在加速针对严重或危及生命疾病的创新疗法的开发和审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170600195","title":"Mesoblast公布Ryoncil®季度淨收入達3030萬美元 運營現金流支出改善至410萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170600195","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170600195?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 08:55","pubTimestamp":1777510516,"startTime":"0","endTime":"0","summary":"生物技术公司Mesoblast Limited（ASX: MSB）最新财报显示，其旗舰产品Ryoncil®在本季度实现净收入3030万美元。与此同时，公司净运营现金支出显著优化，降至410万美元水平。\n财务数据显示，Mesoblast通过精细化运营管理有效控制了成本支出。该公司在保持核心产品收入稳定增长的同时，实现了运营效率的持续提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","BK4588","BK4534","LU0787776722.HKD","MSB.AU","IE000M9KFDE8.USD","BK4585","SG9999002232.USD","LU1988902786.USD","BK7501","LU0683600562.USD","MMM","BK7508","BK4512","BK4533","LU1894683264.USD","SG9999002224.SGD","LU1093756168.USD","LU1064131342.USD","LU1093756325.SGD","BK7067","BK4206","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188850121","title":"異動解讀 | Mesoblast收購CAR平台技術，盤中大漲5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188850121","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188850121?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:19","pubTimestamp":1776212364,"startTime":"0","endTime":"0","summary":"细胞疗法研发企业MESOBLAST LTD（MSB.AU）今日盘中股价大幅上涨5.22%，引起市场关注。消息面上，公司宣布成功收购嵌合抗原受体（CAR）平台技术，该技术将显著提升其细胞产品的精准治疗能力，标志着公司在细胞治疗领域的重大战略布局。通过此次收购整合CAR技术平台，Mesoblast有望开发出更具靶向性和疗效的下一代细胞疗法产品，从而强化其在肿瘤免疫治疗领域的竞争力，为患者提供更精准的个性化治疗方案。这一利好消息直接提振了市场对公司未来发展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180289197","title":"Mesoblast收購嵌合抗原受體平台技術，推動精準增強型細胞產品發展","url":"https://stock-news.laohu8.com/highlight/detail?id=1180289197","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180289197?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:11","pubTimestamp":1776211877,"startTime":"0","endTime":"0","summary":"细胞疗法研发企业MESOBLAST LTD宣布成功收购嵌合抗原受体（CAR）平台技术，该技术将显著提升其细胞产品的精准治疗能力。\n此次收购标志着公司在细胞治疗领域的重大战略布局，通过整合CAR技术平台，有望开发出更具靶向性和疗效的下一代细胞疗法产品。\n该技术平台的引入将强化MESOBLAST LTD在肿瘤免疫治疗领域的竞争力，为患者提供更精准的个性化治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129617691","title":"Mesoblast獲FDA批准 可直接開展Ryoncil®治療杜氏肌營養不良症的註冊試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1129617691","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129617691?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 11:37","pubTimestamp":1775619420,"startTime":"0","endTime":"0","summary":"Mesoblast Limited (ASX: MSB) 已获得美国食品药品监督管理局（FDA）的研究性新药（IND）许可，获准直接推进其核心产品Ryoncil®（瑞洛西尔）用于治疗杜氏肌营养不良症（DMD）的注册临床试验。\n此项关键性监管绿灯意味着，公司无需再进行额外的早期临床研究，即可启动旨在支持该疗法最终上市申请的注册试验阶段。此举显著加快了Ryoncil®针对这一严重遗传性肌肉疾病的开发进程，为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}